When was PharmaMar founded?

PharmaMar was founded in 1986 and raised its 1st funding round 29 years after it was founded.

Where is PharmaMar located?

PharmaMar is headquartered in Colmenar Viejo, Spain.

How many employees does PharmaMar have?

As of Aug 31, 2026, the latest employee count at PharmaMar is 508.

Is PharmaMar a funded company?

PharmaMar is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2015.

When was the latest funding round of PharmaMar?

PharmaMar's latest funding was a $***** Grant (prize money) round on Jun 01, 2021, with participation from 1 investor.

Where does PharmaMar rank among its competitors?

PharmaMar ranks 545th amongst 3318 active competitors, of which 1118 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of PharmaMar?

PharmaMar's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

PharmaMar - 2026 Company Profile, Funding & Competitors

Company Details

PharmaMar is engaged in the discovery of antitumor drugs of marine origin. The company develops and commercializes YONDELIS® (trabectedin) in Europe approved to treat soft tissue sarcoma, ovarian cancer. Also has three clinical-stage programs (Phase 2, Phase 3) under development, in addition to trabectedin, for several types of solid and hematological cancers: PM1183, plitidepsin, and PM184. Trabectedin and Lurbinectedin (or PM1183) are two selective inhibitors of transactivated RNA polymerase II transcription. Plitidepsin inhibits a protein called eEF1A2 which results in higher oxidative stress in tumor cells and triggers cell death; and PM184 inhibits tubulin polymerization.

Website: pharmamar.com
Social

Key Metrics

Founded Year

1986

Location

Colmenar Viejo, Spain

Stage

Public

Latest Funding Round

Grant (prize money), Jun 01, 2021, $*****

Investors

Plexus Ventures & 1 more

Ranked

545^th among 3318 active competitors

Employee Count

508 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2989 more

Exit Details

Public

View PharmaMar's full profile

PharmaMar got listed on Nov 06, 2015.

Click here to take a look at PharmaMar's IPO in detail

PharmaMar has raised funding over 2 rounds. Its first funding round was on Apr 01, 2015. Its latest funding round was a Grant (prize money) round on Jun 01, 2021 for $*****. 1 investor participated in its latest round. PharmaMar has 2 institutional investors.

Here is the list of recent funding rounds of PharmaMar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2021	8692399	Grant (prize money)	9842720	3972611	7536343	6494965
Apr 01, 2015	6531762	Grant (prize money)	7179663	2024699	6220877	Europa

Access funding benchmarks and valuations. Sign up today!

View details of PharmaMar's funding rounds and investors

PharmaMar's employee count trend

PharmaMar has 508 employees as of Aug 26. Here is PharmaMar's employee count trend over the years:

Uncover PharmaMar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PharmaMar include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of PharmaMar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
545th	PharmaMar 1986, Colmenar Viejo (Spain), Public	Developing marine-derived anticancer drugs	-	Plexus Ventures, Europa	51/100